Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-005584

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Jan 24, 2018
Accepted (ET)
Jan 26, 2018 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockJan 24, 2018M20$0.3025A20D
Common stockF3Jan 24, 2018S20$80.01D0D
Common stockF4holding———271,772ISee footnote
Common stockF5holding———79,082ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F6$0.3025Jan 24, 2018M20D—Aug 12, 2019Common stock20141,139D

Explanation of responses